The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis
Front Med (Lausanne)
. 2020 Jul 15;7:312. doi: 10.3389/fmed.2020.00312. eCollection 2020.
Jianhong Wu 1, Jianling Dong 2, Shilin Li 3, Jiaang Luo 2, Yu Zhang 2, Hong Liu 2, Yuanpiao Ni 2, Xue Li 3, Jun Zhou 3, Hang Yang 3, Qianrong Xie 3, Xuejun Jiang 1, Tingting Wang 1, Pingxi Wang 3, Fanwei Zeng 3, Yanpeng Chu 3, Jing Yang 2, Fanxin Zeng 3
From PDF: "VitD was used orally for patients and included calcitriol (0.25 to 0.5 µg/day), or calcium carbonate and vitamin D3 tablets (200 to 400 IU/day)"
Rheumatoid Arthritis category in VitaminDWiki starts with
Highlights of RA studies in VitaminDWiki
RA worse if low Vitamin D
- Rheumatoid Arthritis score extrapolates to zero at 51 ng of Vitamin D (India) – June 2024
- Rheumatoid Arthritis is more severe if low vitamin D – July 2023
- Rheumatoid arthritis pain was 5.8 X more likely if low vitamin D – Aug 2017
- Adaptive and innate immune system, vitamin D genes, and Rheumatoid Arthritis – June 2019
- Rheumatoid Arthritis strongly associated with low vitamin D – meta-analysis April 2016
- Rheumatoid Arthritis associated with lower vitamin D and higher latitude – meta-analysis Jan 2016
- Adaptive and innate immune system, vitamin D genes, and Rheumatoid Arthritis – June 2019
- Resveratrol Role in Autoimmune Disease-A Mini-Review. – Dec 2016
- Immunological effects of vitamin D and their relations to autoimmunity – March 2019
- Arthritis runs in Pakistani families (Vitamin D Receptor) – March 2019
- Juvenile idiopathic arthritis 2.2 X more likely if poor Vitamin D Receptor – Aug 2018
- Juvenile Rheumatoid Arthritis 8 X more likely if poor Vitamin D receptor – Dec 2017
- Inflammation and immune responses to Vitamin D (perhaps need to measure active vitamin D) – July 2017
- Vitamin D in rheumatoid arthritis-towards clinical application – April 2016
- Rheumatoid arthritis is 40 percent more likely if vitamin D Receptor problem – 2 meta-analyses 2015
- Rheumatoid arthritis, genes and vitamin D – May 2013
RA Treated by Vitamin D
- Several rheumatic diseases treated by high-dose vitamin D, but made worse if Calcium was added – April 2022
- Rheumatic Diseases often treated by Vitamin D, may need 40-60 ng – Oct 2021
- Rheumatoid Arthritis pain reduced by monthly 100,000 IU of Vitamin D – Oct 2018
- Rheumatoid arthritis reduced by 440,000 IU of Vitamin D over 4 months – Oct 2015
- Connective tissue disorders (Lupus, RA, etc) treated by vitamin D – May 2016
- 43 percent of Rheumatoid Arthritis patients have Vitamin D prescriptions (15 countries) – June 2017
- Big increase in vitamin D supplementation in just 2 years after Swiss rheumatology report – Dec 2013
- High dose vitamin reduced pain of fibromyalgia, osteoarthritis, and rheumatoid arthritis - July 2015
- Note: Vitamin D receptor problems (such as RA) are best treated by infrequent large doses of Vitamin D
Download the PDF from VitaminDWiki
Background: The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA).
Methods: This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections.
Results: At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups (p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups.
Conclusion: VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.
| 2642 visitors, last modified 09 Aug, 2020, |